



Press Release

Strides Shasun Limited
(Formerly Strides Arcolab Limited)
Strides House, Bannerghatta Road,
Bangalore – 560076.

Strides Shasun receives USFDA Approval for Ranitidine Tablets

First Integrated product approval post Merger

Bangalore, August 24, 2016, Strides Shasun Limited today announced that it has received approval from the United States Food & Drug Administration (USFDA) for **Ranitidine Tablets USP, 150 mg and 300 mg**.

Ranitidine tablet is the first integrated product approval where the API and formulations will be manufactured at erstwhile Shasun Pharmaceutical's Cuddalore and Pondicherry facilities respectively.

According to IMS data (MAT June 2016), the US market for Ranitidine Tablets USP, 150 mg and 300 mg. is approximately USD 125 Million.

The product to be launched immediately will be marketed by Strides Pharma Inc in the US Market.

About Ranitidine Tablets

Ranitidine is used to treat ulcers of the stomach and intestines and prevent them from coming back after they have healed. This medication is also used to treat certain stomach and throat problems. Ranitidine belongs to a class of drugs known as H2 blockers.

About Strides Shasun Limited

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Pharmaceutical Services & Active Ingredients.

The Company has global manufacturing foot print with 14 manufacturing facilities spread across three continents including 6 US FDA approved facilities and 8 facilities for the emerging markets. The Company has three dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries. Additional information is available at the Company's website at www.stridesarco.com

For further information, please contact:

<p><u>Strides Shasun</u></p> <p>Badree Komandur, Group CFO +91 80 6784 0747</p> <p>Vikesh Kumar +91 80 6784 0827 Kannan. N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791</p>	<p><u>PR Consultancy</u></p> <p>Fortuna PR K Srinivas Reddy: +91 90005 27213 srinivas@fortunapr.com</p> <p>K Priya: +91 95354 25418 priya@fortunapr.com</p>
---	--